PMID- 19936876
OWN - NLM
STAT- MEDLINE
DCOM- 20100318
LR  - 20211020
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 90
IP  - 5
DP  - 2009 Dec
TI  - Phase I/II study of tandem high-dose chemotherapy with autologous peripheral 
      blood stem cell transplantation for advanced multiple myeloma.
PG  - 635-642
LID - 10.1007/s12185-009-0445-8 [doi]
AB  - The efficacy and safety of high-dose chemotherapy with tandem autologous 
      peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in a 
      multicenter clinical study of patients with advanced multiple myeloma. Eligible 
      patients (n = 40) were consecutively enrolled in the phase I/II study and 
      received 2-4 cycles of vincristine-adriamycin-dexamethasone regimen. The 
      responding patients underwent PBSC harvesting following high-dose 
      cyclophosphamide and filgrastim administration. The first auto-PBSCT (n = 32) 
      following high-dose melphalan (200 mg/m(2)) was performed within 2 months of PBSC 
      harvesting; the second auto-PBSCT (n = 28) was scheduled 3-6 months later. 
      Treatment-related mortality was 2.5% (n = 1) throughout the protocol. Grade 4 
      nonhematologic toxicity occurred in 12.5 and 14.3% of the first and second 
      auto-PBSCT patients, respectively. All but one patient (who died) achieved 
      hematopoietic recovery. For the 28 patients completing the second auto-PBSCT, the 
      results were favorable with a response rate of 65% (complete response rate = 
      27.5%, n = 11); the five-year progression-free survival and overall survival were 
      20.3 and 66.5%, respectively. In conclusion, high-dose chemotherapy with tandem 
      auto-PBSCT is feasible and safe with a favorable response rate in treating 
      advanced multiple myeloma in Japan.
FAU - Sunami, Kazutaka
AU  - Sunami K
AD  - Division of Hematology, Department of Internal Medicine, National Hospital 
      Organization Okayama Medical Center, 1711-1 Tamasu, Kitaku, Okayama, 701-1192, 
      Japan. kazusuna@pop12.odn.ne.jp.
FAU - Shinagawa, Katsuji
AU  - Shinagawa K
AD  - Division of Hematology/Oncology, Okayama University Medical School, Okayama, 
      Japan.
FAU - Sawamura, Morio
AU  - Sawamura M
AD  - Department of Internal Medicine, Nishigunma National Hospital, Shibukawa, Gunma, 
      Japan.
FAU - Sakai, Akira
AU  - Sakai A
AD  - Department of Hematology/Oncology, Institute for Rad. Biology and Medicine, 
      Hiroshima University, Hiroshima, Japan.
FAU - Saburi, Yoshio
AU  - Saburi Y
AD  - Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
FAU - Imamura, Yutaka
AU  - Imamura Y
AD  - Division of Hematology, St. Mary's Hospital, Kurume, Fukuoka, Japan.
FAU - Mizuno, Ishikazu
AU  - Mizuno I
AD  - Hematology Division, Department of Medicine, Hyogo Cancer Center, Akashi, Hyogo, 
      Japan.
FAU - Tamaki, Shigehisa
AU  - Tamaki S
AD  - Department of Internal Medicine, Yamada Red Cross Hospital, Ise, Mie, Japan.
FAU - Kamimura, Tomohiko
AU  - Kamimura T
AD  - Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.
FAU - Tsuda, Hiroyuki
AU  - Tsuda H
AD  - Division of Hematology/Oncology, Kumamoto City Hospital, Kumamoto, Japan.
FAU - Gondo, Hisashi
AU  - Gondo H
AD  - Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
FAU - Hino, Norihiko
AU  - Hino N
AD  - Department of Internal Medicine, Kure Kyosai Hospital, Kure, Hiroshima, Japan.
FAU - Shimazaki, Chihiro
AU  - Shimazaki C
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, Kyoto, Japan.
FAU - Miyata, Akira
AU  - Miyata A
AD  - Department of Internal Medicine, Chugoku Central Hospital of the Mutual Aid 
      Association of Public School Teachers, Fukuyama, Hiroshima, Japan.
FAU - Tajima, Fumihito
AU  - Tajima F
AD  - Division of Blood Transfusion, Tottori University Hospital, Yonago, Tottori, 
      Japan.
FAU - Takemoto, Yoshinobu
AU  - Takemoto Y
AD  - Medical Corporation Kouryokai CPC Clinic, Kagoshima, Japan.
FAU - Miwa, Akiyoshi
AU  - Miwa A
AD  - Department of Hematology, International Medical Center of Japan, Tokyo, Japan.
FAU - Chou, Takaaki
AU  - Chou T
AD  - Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
FAU - Harada, Mine
AU  - Harada M
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School 
      of Medical Science, Fukuoka, Japan.
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20091121
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 5J49Q6B70F (Vincristine)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Combined Modality Therapy/methods/mortality
MH  - Dexamethasone/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Humans
MH  - Multiple Myeloma/mortality/*therapy
MH  - Peripheral Blood Stem Cell Transplantation/*methods
MH  - Survival Rate
MH  - Transplantation, Autologous
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage
EDAT- 2009/11/26 06:00
MHDA- 2010/03/20 06:00
CRDT- 2009/11/26 06:00
PHST- 2008/11/03 00:00 [received]
PHST- 2009/10/29 00:00 [accepted]
PHST- 2009/10/29 00:00 [revised]
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/03/20 06:00 [medline]
AID - 10.1007/s12185-009-0445-8 [pii]
AID - 10.1007/s12185-009-0445-8 [doi]
PST - ppublish
SO  - Int J Hematol. 2009 Dec;90(5):635-642. doi: 10.1007/s12185-009-0445-8. Epub 2009 
      Nov 21.